Hans-Peter Boeck

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel, Ulrich Kaiser, Christina Balser et al. · The Lancet Oncology · 2015 · 153 citations

Medicine, Oncology, Pharmacotherapy +14

Prospective, Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase III Study with Orally Administered Budesonide for Prevention of Irinotecan (CPT-11)-Induced Diarrhea in Patients with Advanced Colorectal Cancer

Meinolf Karthaus, Harald Balló, W. Abenhardt et al. · Oncology · 2005 · 49 citations

Medicine, Oncology, Pharmacotherapy +17

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, Martin Dreyling, Hartmut Eimermacher et al. · Blood · 2004 · 21 citations

Medicine, Immunology, Oncology +9